title: Resistant nonunions and partial or complete segmental defects of long bones. Treatment with implants of a composite of human bone morphogenetic protein (BMP) and autolyzed, antigen-extracted, allogeneic (AAA) bone.
abstract: Twenty-five patients with resistant nonunions including partial or complete segmental defects were treated with a composite alloimplant of human bone morphogenetic protein (h-BMP) and autolyzed, antigen-free, allogeneic bone (AAA). The series consisted of 16 females and nine males; average age was 45 years. Preoperative symptoms averaged 30 months (range, five to 83 months); 22 of 25 patients had failed multiple attempts at electrical stimulation. Twenty-three of 25 patients had an average of three prior failed surgical attempts at union (range, one to ten). There were ten segmental defects with an average length of 4 cm (range, 2-9 cm). The composite implant was incorporated as an onlay in 15 extremities and as an inlay graft supported by internal fixation in ten extremities. Seven patients received supplementary autogeneic cancellous bone grafting. Average healing time was six months (range, three to 14 months). Average follow-up time was 21 months (range, five to 82 months). Functional results were rated as excellent, 14; good, five; and fair, five. One failed to unite because of a recurrent infection. Union was obtained in 24 of 25 patients. There were five failures of the original operation that required reoperations; union eventually occurred in four of five extremities by repeat composite grafting and replacement of the failed internal fixation. Bony union between host bone and the composite implant began at an average of eight weeks postoperatively. Present results indicate that h-BMP/AAA composite implants represent adjunctive treatment of difficult nonunions. The h-BMP/AAA composite implants may be implanted in either partial or complete segmental defects of long bones.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Bone Research Laboratory, University of California (UCLA), Los Angeles.
authors.forename: E E
authors.initials: EE
authors.lastname: Johnson
authors.forename: M R
authors.initials: MR
authors.lastname: Urist
authors.forename: G A
authors.initials: GA
authors.lastname: Finerman
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D019485:Bone Morphogenetic Proteins; D016025:Bone Transplantation / Q000379:methods*; D003131:Combined Modality Therapy; D005260:Female; D005264:Femoral Fractures / Q000628:therapy; D005593:Fracture Fixation, Internal / Q000379:methods; D005599:Fractures, Ununited / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000628:therapy*; D006133:Growth Substances / Q000627:therapeutic use*; D006801:Humans; D006810:Humeral Fractures / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011506:Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D011859:Radiography; D011994:Recombinant Proteins / Q000627:therapeutic use; D013978:Tibial Fractures / Q000628:therapy; D014184:Transplantation, Homologous; D014945:Wound Healing
chemical_list: D019485:Bone Morphogenetic Proteins; D006133:Growth Substances; D011506:Proteins; D011994:Recombinant Proteins